Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and MEK inhibition progress within 6 months. Treatment options for these patients remain limited. Here we analyse 20 BRAF(V600)-mutant melanoma metastases derived from 10 patients treated with the combination of dabrafenib and trametinib for resistance mechanisms and genetic correlates of response. Resistance mechanisms are identified in 9/11 progressing tumours and MAPK reactivation occurred in 9/10 tumours, commonly via BRAF amplification and mutations activating NRAS and MEK2. Our data confirming that MEK2(C125S), but not the synonymous MEK1(C121S) protein, confers resistance to combination therapy highlight the functional differences between these kinases and the preponderance of MEK2 mutations in combination therapy-resistant melanomas. Exome sequencing did not identify additional progression-specific resistance candidates. Nevertheless, most melanomas carried additional oncogenic mutations at baseline (for example, RAC1 and AKT3) that activate the MAPK and PI3K pathways and are thus predicted to diminish response to MAPK inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In cell lines and xenografts, intrinsic and acquired resistance to signaling pathway inhibitors against estrogen, RAF, EGFR, PI3K, and others is sometimes associated with mutations in p16Ink4a, upregulated expression of cyclin D1 or other D-type cyclins, or upregulation of CDK4 or CDK6 (Jiang et al., 2016; Long et al., 2014; Yadav et al., 2014).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Long et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., Philippakis, A. A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,456
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Self-citationA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Cited by
Items 301–380 of 380
Németh, A., Bányai, G. L., Dobos, N. K., Kós, T., Gaál, A., Varga, Z., Buzás, E. I., Khamari, D., Dank, M., Takács, I., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01660-4 · Cited by 5
“However, after prominent disease regression, resistance to dabrafenib-trametinib therapy still recurrently develops [55, 63, 64].”
BackgroundCurrent and emerging treatment options for BRAFV600-mutant melanoma
Javaid, A., Peres, T., Pozas, J., Thomas, J. M., & Larkin, J. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2451722 · Cited by 2
Fischer, G. M., Fang, R., Xu, S., Karkempetzaki, A. I., Migayron, L., Draper, E. C., Wang, J., Schatton, T., Mandinova, A., Murphy, G. F., et al. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf378 · Cited by 4
A second chance for success with BRAF and MEK inhibitors in melanoma
Paulson, K. G., & Thompson, J. A. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30151-1 · Cited by 2
Self-citationBeating tumour drug resistance: “Lamarckian” induction in the spotlight
Robles‐Espinoza, C. D. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12744 · Cited by 2
“Accordingly, studies of the acquisition of resistance in BRAFi/MEKi‐treated tu‐ mours have shown reactivation of the MAPK pathway through mechanisms such as BRAF amplification, mutations of MEK and on‐ cogenic mutations in NRAS (Long et al., 2014).”
BackgroundInfluentialGeometric and Combinatorial Aspects of NonEquilibrium Statistical Mechanics
Polettini, M. (2012) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.6092/unibo/amsdottorato/4305 · Cited by 6
Miley, D. R., Andrews-Pfannkoch, C. M., Pulido, J. S., Erickson, S. A., Vile, R. G., Fautsch, M. P., Marmorstein, A. D., & Dalvin, L. A. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000921 · Cited by 2
“Despite good initial efficacy, the impact on normal cells can lead to dose-limiting toxicities [5,6], and a large proportion of patients will develop acquired treatment resistance within 6–7 months [4,9,10].”
BackgroundDatta, K. K., Kore, H., & Gowda, H. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114215 · Cited by 2
Liu, F., & Lin, J. (2024) · Cancers · doi:10.3390/cancers16132313 · Cited by 2
“While most phenotype data was downloaded from the GEO website, some patient information was extracted from original publications [9–11].”
BackgroundMethodInfluentialChen, L., Pruteanu-Malinici, I., Dastur, A., Yin, X., Frederick, D. T., Sadreyev, R. I., & Benes, C. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-86694-5 · Cited by 1
Zhang, P., Zhang, Y., Sun, Y., Chen, Y., Cao, X. M., He, Y., Tan, Y., Zhang, Z., Deng, S., Zhou, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01055 · Cited by 1
Unravelling the crosstalk: Anti-fibrotic agents and MAPK inhibitors in the treatment of melanoma
Swathika, R., Nayak, Y., Prasad, A. S. B., & Nayak, U. Y. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105084 · Cited by 1
Challenges and opportunities for treating intrahepatic cholangiocarcinoma: targeted therapy
Gim, G., & Badri, N. (2023) · Hepatoma Research · doi:10.20517/2394-5079.2023.90 · Cited by 3
Wittsten, A. H., Sturesson, H., Bidgoli, M., Jonson, T., Ehinger, M., Lilljebjörn, H., Scheding, S., & Andersson, A. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22384 · Cited by 1
20 YEARS OF TARGETING THERAPY OF SOLID TUMORS. SUCCESSES AND FAILURES
Tryakin, A. A., Fedyanin, M. Y., & Покатаев, И. А. (2018) · Practical oncology · doi:10.31917/1903183 · Cited by 2
BRAF: Novel Therapies for an Emerging Target
Myall, N. J., & Padda, S. K. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_4 · Cited by 1
Antitumor Effect of Metformin in Combination with Binimetinib on Melanoma Cells
Lee, E., Kwon, Y., Kim, J., Park, D., & Lee, Y. (2021) · Development & Reproduction · doi:10.12717/dr.2021.25.2.93 · Cited by 1
Author response: Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression
Anelli, V., Villefranc, J. A., Chhangawala, S., Martinez-McFaline, R., Riva, E., Nguyen, A., Verma, A., Bareja, R., Chen, Z., Scognamiglio, T., et al. (2017) · eLife · doi:10.7554/elife.20728.020 · Cited by 1
Kinsler, V. A. (2019) · Harper's Textbook of Pediatric Dermatology · doi:10.1002/9781119142812.ch105 · Cited by 1
Alderton, G. K. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3889
Clinical aspects of molecular profiles in metastatic malignant melanoma
Ekedahl, H. (2017) · Lund University Publications (Lund University)
Will melanoma be curable? Perspectives in melanoma therapy
Lengyel, Z., Baltás, E., & Gyulai, R. (2017) · Bőrgyógyászati és Venerológiai Szemle · doi:10.7188/bvsz.2017.93.4.7
Meierjohann, S., & Schilling, B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00046-6
Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy
Pinho, A. V., Lee, J., & Rizos, H. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-21477-7_8
Self-citationTARGETING THE ERK MAPK PATHWAY IN RAS-DRIVEN CANCERS
Ryan, M. B. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/jjj1-7f72
Fenton, S. E., Sosman, J. A., & Chandra, S. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.86615 · Cited by 1
Analysis of Amino Acid Variants in Malignant Melanoma Cells Resistant to BRAF inhibitionPreprint
Schmitt, M., Sinnberg, T. W., Bratl, K., Zittlau, K., Garbe, C., Maček, B., & Nalpas, N. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.15.422879
“nucleotide variants identified in A375 R against the study from Long and colleagues (20), who 349 analysed 10 malignant melanoma patients (Table S2.”
BackgroundMethodOncogenic variants guiding treatment in thoracic malignancies
Meng, P. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.160074057
Assessment of the clinical validity of ctDNA Analysis for melanoma management
Marsavela, A.-G. (2021) · Research Online (Edith Cowan University)
Incorporating Circulating Biomarkers into Clinical Trials
Jankú, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-47682-3_14
Yu, Y., Tao, M., Xu, L., Cao, L., Le, B., An, N., Dong, J., Xu, Y., Yang, B., Li, W., et al. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0560 · Cited by 1
Metastatic melanomas: Treatment overview
Nerkar, A. G. (2021) · Current Trends in Pharmacy and Pharmaceutical Chemistry · doi:10.18231/j.ctppc.2021.013
Heinzerling, L., Hartmann, A., & Hund, M. (2019) · Springer eBooks · doi:10.1007/978-3-662-58012-7_1
Huang, F., Cai, F., Dahabieh, M. S., Gunawardena, K., Talebi, A., Dehairs, J., El-Turk, F., Park, J. Y., Gonçalves, C., Gagnon, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.25.513718
“public database, accession numbers GSE99898, GSE61992 and GSE50509 (42-44).”
BackgroundMethodData from ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy
Jaiswal, B. S., Durinck, S., Stawiski, E. W., Yin, J., Wang, W., Lin, E., MOFFAT, J. B., Martin, S. E., Modrusan, Z. D., & Seshagiri, S. (2023) · doi:10.1158/1078-0432.c.6529128.v1
Data from ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy
Jaiswal, B. S., Durinck, S., Stawiski, E. W., Yin, J., Wang, W., Lin, E., MOFFAT, J. B., Martin, S. E., Modrusan, Z. D., & Seshagiri, S. (2023) · doi:10.1158/1078-0432.c.6529128
Ortiz‐Cuaran, S., Mezquita, L., Swalduz, A., Aldea, M., Mazières, J., Léonce, C., Jovelet, C., Pradines, A., Avrillon, V., Flores, W. R. C., et al. (2023) · doi:10.1158/1078-0432.c.6530096.v1
Sasame, J., Ikegaya, N., Kawazu, M., Natsumeda, M., Hayashi, T., Isoda, M., Satomi, K., Tomiyama, A., Oshima, A., Honma, H., et al. (2023) · doi:10.1158/1078-0432.c.6532446
Izquierdo, E., Carvalho, D. M., Mackay, A. G., Temelso, S., Boult, J. K. R., Pericoli, G., Fernandez, E., Das, M., Molinari, V., Grabovska, Y., et al. (2025) · doi:10.1158/2159-8290.c.6549665
Chen, J., Fang, C., Chang, C., wang, K., Jin, H., Xu, T., hu, J., wu, W., Shen, E., & Zhang, K. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4532529
Kosnopfel, C., Wendlinger, S., Niessner, H., Siewert, J., Sinnberg, T. W., Hofmann, A., Wohlfarth, J., Schrama, D., Berthold, M., Siedel, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23706995
The phenomenon of the BRAF and TERTp mutational duet in melanoma and other cancers
Rusinek, D., Pfeifer, A., Zajkowicz, A., Tęcza, K., Pamuła‐Piłat, J., Czarnecka, A. M., & Oczko‐Wojciechowska, M. (2024) · Nowotwory Journal of Oncology · doi:10.5603/njo.103026
Wei, B., Verdi, V., Zhang, S., Mock, B. A., Shive, H. R., & Simpson, R. J. (2025) · Cancers · doi:10.3390/cancers17142357
“Despite initial efficacy, most patients eventually develop trametinib resistance [37,38], which underscores the need for research into resistance mechanisms and countermeasures.”
VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activationPreprint
Hwang, S., Bae, M., Kim, J., Hyun, S. Y., Kim, K., Choe, J. H., Kim, M. J., Park, J. W., Jeong, S., Choi, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.16.676456
Sultan, M., Ma, S., Diez, J., Velayutham, S., Alharbi, Y. N., Choi, J. Y., Smalley, K. S. M., Nathanson, L., Beljanski, V., & Minond, D. (2025) · Biomolecules · doi:10.3390/biom15111611
“Current treatments for melanoma face significant limitations, including low response rates (RRs), a lack of effective therapies for triple-wild-type and NRAS-mutant melanoma [3], and drug resistance [4,5].”
He, X., Xie, S., Jia, C., Wu, X., Chen, Z., & wang, T. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf374
Kosnopfel, C., Wendlinger, S., Niessner, H., Siewert, J., Sinnberg, T. W., Hofmann, A., Wohlfarth, J., Schrama, D., Berthold, M., Siedel, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23706986
Kosnopfel, C., Wendlinger, S., Niessner, H., Siewert, J., Sinnberg, T. W., Hofmann, A., Wohlfarth, J., Schrama, D., Berthold, M., Siedel, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23706989
Kosnopfel, C., Wendlinger, S., Niessner, H., Siewert, J., Sinnberg, T. W., Hofmann, A., Wohlfarth, J., Schrama, D., Berthold, M., Siedel, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23706983
Park, B.-S., Jeon, H., Kim, Y., Kwon, H., Choi, G.-E., Chi, S.-G., Park, H.-M., Lee, H., & Kim, T. (2024) · Figshare · doi:10.6084/m9.figshare.26182227
Kosnopfel, C., Wendlinger, S., Niessner, H., Siewert, J., Sinnberg, T. W., Hofmann, A., Wohlfarth, J., Schrama, D., Berthold, M., Siedel, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23706992
Kosnopfel, C., Wendlinger, S., Niessner, H., Siewert, J., Sinnberg, T. W., Hofmann, A., Wohlfarth, J., Schrama, D., Berthold, M., Siedel, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23706998
Puyalto, A., Rodríguez‐Remírez, M., López, I., Macaya, I., Guruceaga, E., Olmedo, M., Vilalta, A., Welch, C., Sandiego, S., Vicent, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26709569
Park, B.-S., Jeon, H., Kim, Y., Kwon, H., Choi, G.-E., Chi, S.-G., Park, H.-M., Lee, H., & Kim, T. (2024) · Figshare · doi:10.6084/m9.figshare.26182309
Kosnopfel, C., Wendlinger, S., Niessner, H., Siewert, J., Sinnberg, T. W., Hofmann, A., Wohlfarth, J., Schrama, D., Berthold, M., Siedel, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23706980
Puyalto, A., Rodríguez‐Remírez, M., López, I., Macaya, I., Guruceaga, E., Olmedo, M., Vilalta, A., Welch, C., Sandiego, S., Vicent, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26709572
Kosnopfel, C., Wendlinger, S., Niessner, H., Siewert, J., Sinnberg, T. W., Hofmann, A., Wohlfarth, J., Schrama, D., Berthold, M., Siedel, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23706974
Kosnopfel, C., Wendlinger, S., Niessner, H., Siewert, J., Sinnberg, T. W., Hofmann, A., Wohlfarth, J., Schrama, D., Berthold, M., Siedel, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23706971
Garcia-Perez, A., Sanchez-Garcia, L., Duran-Renieblas, M., Sella, F., Novo-Acedo, S., Delgado-Lopez, A., Barreno, A., Gracia, J., Rios, C., Young, E. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.03.686756
Kumari, A., Meher, N., Dey, A., Awasthi, S., Saraf, S. A., & Srivastava, N. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117754
Parmar, V., Lodde, G. C., Haubold, J., Hosch, R., Borys, K., Nensa, F., Chodyla, M.-K., Holtkamp, M., Forsting, M., Schadendorf, D., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116690
Marqueurs prédictifs de réponse aux inhibiteurs de BRAF dans le mélanome cutané métastatique
Funck-Brentano, E. (2016) · theses.fr (ABES) · doi:10.70675/73a2af67z6d03z483czb461zb0527aec1a30
Radiothérapie interne du mélanome métastatique pigmenté : mécanismes et associations
Rouanet, J. (2019) · theses.fr (ABES) · doi:10.70675/c28349fdz1635z480bzb4e7za5f431ee26c8
Lee, S., Kim, Y. H., Heo, B. S., Cheon, C., & Ko, S. (2026) · Cancer Science · doi:10.1111/cas.70387
“Dual inhibition of BRAF and MEK has yielded enhanced efficacy; however, resistance development continues to limit its clinical utility [31].”
Synovial Sarcoma With BRAF V600E Mutation: A Case Report and Literature Review
Gao, T., Deng, T., Shi, Y., Yang, F., Xiao, S., & Fan, Z. (2026) · Genes Chromosomes and Cancer · doi:10.1002/gcc.70128
Slika, I., Edwards, C. K., Cohen, K. J., Friedman, A. D., Pratilas, C. A., & Odeniyide, P. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1819524
Wang, Z., Liu, H. M., Wang, X., Teng, J., Zheng, Z., Zhang, J. I.-X., Xiao, W., Liang, Q., Li, J., Jia, X., et al. (2026) · Advanced Science · doi:10.1002/advs.202515158
“Key mediators of cross-resistance have been identified, including reactivation of the MAPK pathway and dysregulation of Hippo signaling [ 9, 10 ].”
Schlachtenberger, G., Goitom, A., Amorin, A., Lopez‐Pastorini, A., Merres, J., Gaisendrees, C., & Heldwein, M. B. (2026) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-026-02310-x
Toda, S., Hiroshima, Y., Iwasaki, H., Kadoya, M., Suzuki, C., Yamazaki, H., Okubo, Y., Saito, A., & Masudo, K. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00520 · Cited by 1
Paulrasu, K., Ali, H., Marudamuthu, A., Thada, S., Halder, U., Adam, P., Gourishetti, K., Thirunavukkarasu, B., Dhanasekaran, M., Minond, D., et al. (2026) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2026.100368 · Cited by 1
Fu, H., Wang, M., Zhu, H., Li, W., Shen, X., Yan, H., & He, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188031
“For clinical translation and survival analysis, public clinical transcriptomic and survival data from 48 BRAF V600E-mutant melanoma patients were collected across six independent cohorts: GSE50509 [34], GSE50535 [6], GSE61992 [35], GSE65185 [36], GSE77940 [37], and GSE99898 [38] (Table S4).”
Therapeutic Resistance in Melanoma: Molecular Mechanisms and Emerging Pharmaceutical Strategies
Moussallem, N., Awada, A., Darzi, R. E., Tarhini, A., Khaled, A., Ashy, C., Nasr, W., Masri, A. E., Saad, G., Itani, M. H., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19091455 · Cited by 2
“These mechanisms include, but are not limited to, genetic and signaling alterations, transcriptional reprogramming, and metabolic adaptations [69,70].”
InfluentialCancer pharmacomicrobiomics: Targeting microbiota to optimize cancer therapy outcomes
Punuri, S. V., Dagar, W., Vodnala, S., Bhyan, B., & Jangra, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33206-7.00011-x
BindingDB (2023) · UC San Diego · doi:10.7270/q2c82f6m
BindingDB (2021) · UC San Diego · doi:10.7270/q23x89xq
Metadata
- Authors
- Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., Howle, J., Hayward, N. K., Johansson, P., Scolyer, R. A., Kefford, R. F., & Rizos, H.
- Affiliations
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Corresponding author
- Rizos, Helen
- ORCID
- Venue
- Nature Communications
- Published
- 2014-12-02
- Volume
- 5
- Issue
- 1
- Pages
- 5694-5694
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2003402062
- Cited by
- 375
- References
- 62
- Citations by year
- 2026: 16 · 2025: 21 · 2024: 27 · 2023: 44 · 2022: 26 · 2021: 35 · 2020: 36 · 2019: 33 · 2018: 33 · 2017: 43 · 2016: 34 · 2015: 24 · 2014: 1
- FWCI
- 13.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Communications (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Westmead Millennium Institute for Medical Research
- Australian Cancer Research Foundation
- Cancer Institute NSW
- Melanoma Institute Australia
- Medical Research Council
- National Health and Medical Research Council (633004)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- dabrafenib, trametinib, combination therapy resistance, MAPK pathway reactivation, BRAF amplification, NRAS mutation, PI3K signaling, Rac1, AKT3, BRAF V600E mutation, resistance mechanisms
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Humans, Imidazoles, Melanoma, Membrane Proteins, Oximes, Pyridones, Pyrimidinones, Skin Neoplasms, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, GTP Phosphohydrolases, rac1 GTP-Binding Protein, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.